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Abstract
&
Rett syndrome was associated with low cer-
ebrospinal fluid (CSF) 5-methyltetrahydro-
folate (5MTHF) in 42 – 50 % of European patients
whereas approximately 93 % of the patients
from North-America had a normal CSF 5MTHF
status. We determined the CSF folate status in
Rett patients living in North- and South-Western
Europe and measured serum folate receptor (FR)
autoantibodies of the blocking type to explain
the reduced folate transport across the choroid
plexus. Irrespective of their MECP2 genotype
els. Blocking FR autoantibodies were found in 8
of the Rett patients (24 % ), 6 of whom had low
CSF folate levels. FR autoimmunity was prima-
rily found within the group of Rett patients with
low CSF folate status with a higher incidence in
North-Western Europe. In Rett patients from
North-America 74 of 76 girls had higher folate
values in both serum and CSF than European
patients. The food folate fortification in North-
America may account for the higher folate levels
and may prevent CFD in these Rett patients. FR
autoimmunity occurred predominantly in Rett
patients from North-Western Europe and may
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Serum FR autoantibodies of the blocking type
have been associated with the infantile-onset
CFD syndrome whereas in age-matched controls
and in serum from subjects with central nervous
system disease unrelated to cerebral folate defi-
ciency these FR autoantibodies were absent. In
vitro studies substantiated the blocking action of
these FR autoantibodies that form a complex
with the FR at its folate-binding site and thus
impairs the binding of 5-methyltetrahydrofolate
(5MTHF) to the FR [5] . Recent studies now have
confirmed an inverse correlation between the
titer of the serum FR autoantibodies and the CSF
5MTHF levels (unpublished results).
In order to explain the low CSF folate in 42 – 50 %
of Rett patients due to reduced folate transport
into the CNS, serum samples from all study par-
ticipants were analysed for blocking autoanti-
bodies against the folate receptors (FRs).
Methods
&
According to the internationally defined clinical
criteria for Rett syndrome, thirty-three girls with
Introduction
&
After intestinal absorption of food-derived folates,
intestinal cells will convert folate compounds to
5MTHF, which represents the predominant and
only reduced folate form in plasma which is able
to cross the blood-brain barrier. Plasma 5MTHF is
actively transported into the spinal fluid com-
partment by folate receptor (FR) endocytosis at
choroid epithelial cells. Approximately 42–50% of
Rett patients from Europe and Israel were previ-
ously reported to have a reduced concentration
of 5-methyltetrahydrofolate (5MTHF) in the cer-
ebrospinal fluid (CSF) [1 – 3] . Oral folinic acid sup-
plementation restored 5MTHF levels in the spinal
fluid with partial clinical improvement and bet-
ter seizure control [1, 3] . The reduced folate in the
CSF could not be attributed to abnormalities of
the FR1 or FR2 genes and was independent of
methyl-CpG binding protein (MECP2) status [1] .
A recent study from North America reported that
only 2 of 76 female Rett patients had a low spinal
fluid 5MTHF level [4] .
and despite normal plasma folate values, 14 of33 Rett patients (42 % ) had low CSF folate lev- contribute to cerebral folate deficiency (CFD). 
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Table 1 Age, genotype and laboratory findings in European Rett girls
Patient Age years MECP2
genotype
Serum folate
nmol / L *
CSF 5MTHF
nmol / L §
Folate Ratio
CSF / serum
Autoantibodies
pmol FRs / ml
AED
1 13.5 normal 47 15 0.32 1.22 none
2 4.3 normal 16.5 12 0.72 1.5 E
3 5.7 normal 22.5 30.9 1.3 1.63 none
4 3.8 R106W ND 14.1 – 2.04 none
5 13.1 P152R 33.22 12.5 0.37 0.3 none
6 13 dup 763 – 775 13.2 17 1.28 1.78 none
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a classical Rett phenotype were selected for this study [6] . Com-
plete genetic analysis of the MECP2 gene revealed abnormalities
in 21 of the 33 patients. Epileptic seizures were found in 15 of 33
Rett patients, for which anticonvulsant drugs were adminis-
tered. All patients whose serum and red blood cell folate levels
were normal, underwent a spinal tap to determine the concen-
tration of 5MTHF in the CSF. Eight girls with Rett syndrome lived
in North-Western Europe (patient 1 – 6 in Germany; patient 7,8
in Belgium), while 25 patients resided in Southern Europe
(patients 9 – 19 in Spain; patients 20 – 33 in Portugal)( ••Table 1).
Age-related references for 5MTHF in the CSF have been estab-
lished for both populations from North-Western and South-
Western Europe [5, 7] .
To determine the cause of reduced 5MTHF in the CSF, serum
samples were analyzed for the presence of blocking autoanti-
The Fisher exact test was also applied to compare the incidence
of cerebral folate deficiency (CFD) between Rett patients from
Europe and North-America, and to determine the incidence of
FR autoantibodies in Rett patients in Europe and healthy con-
trols. Statistical analysis used the analysis of variance for inde-
pendent samples to compare the serum and CSF folate values
between the European Rett population, North-American Rett
population and healthy controls. The analysis of variance was
also used to compare the CSF folate levels between Rett girls
residing in North-Western, South-Western parts of Europe and
healthy controls. Data have been used from a study on North-
American Rett girls and from the available data on serum folate
extracted from the American National Health and Nutrition
Examination Survey 1999 – 2000 [4, 8] .
7 4 del exon 2 – 3 19 45 2.36 negative V
8 6 del G 483 29.24 68 2.32 negative none
9 6 normal ND 92 – negative none
10 16 R294X ND 68 – negative C
11 19 normal 8.8 38 4.31 negative C + R
12 11 normal ND 73 – negative V + E
13 3 S229L 34.7 40 1.15 negative V
14 5 R306C 45 64 1.45 negative C
15 2 R255X 15.1 47 3.13 0.29 none
16 2 normal 62.2 65 1.04 negative V
17 2 Y141X 40 69 1.72 negative none
18 4 P302H 9.4 34 3.6 negative V
19 10 R306C 9.9 33 3.3 negative C + R
20 5.6 R294X 20,15 46 2.28 negative none
21 15.5 K39fsX43 14.49 42 2.89 negative V + C
22 10.9 R133C ND 41 – negative none
23 4.9 R294X 22.8 43 1.88 negative none
24 7.1 R168X 17.21 40 2.32 negative V + C
25 3.4 normal 14.94 57 3.81 negative none
26 9.3 normal 27.18 48 1.76 0.34 none
27 6.4 normal 19.93 42 2.10 negative none
28 5.6 normal 21.06 45 2.13 negative none
29 16.3 R168X 20.38 54 2.64 negative V + C
30 2.8 T158M 19.70 58 2.93 negative none
31 15.7 normal 12.45 46 3.69 negative V + C
32 3.7 R294X 40.54 42 1.03 negative none
33 6.6 T158M 25.59 61 2.38 negative V
Patient 1 – 8 from Northern Europe and patient 9 – 33 from Southern Europe. ND = not determined
* Serum folate for healthy controls with a mean at 24.72 and range 8.3 – 45 nmol / L
§ CSF folate values below the reference range have been indicated by bold numbers. Reference range of CSF 5MTHF for healthy controls from Northern Europe, 0 – 1 years
64 – 182 nmol / L, 2 – 4 years 63 – 111 nmol / L, 5 – 10 years ’ 41 – 117 nmol / L, 11 – 16 years 41 – 117 nmol / L, > 16 years 41 – 117 nmol / L
Reference range of CSF 5MTHF for healthy controls from South-Europe, aged 0 – 1 years 63 – 129 nmol / L, 2 – 3 years 44 – 122 nmol / L, 4 – 18 years 42 – 81 nmol / L
Abbreviation for anticonvulsant drugs: V: Valproate; C: Carbamazepine; R: Clonazepam; E: Ethosuximide 
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bodies against the FRs using previously reported methods [5] .
Statistical analysis used the Fisher exact test to compare the
incidence of low CSF folate and FR autoimmunity among the two
groups from North-Western and South-Western Europe, and to
study the association of FR autoimmunity with CSF folate status.
Results
&
Compared to North-American Rett patients and healthy Euro-
pean controls, the 33 Rett girls from Europe had a statistically
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Table 2 Comparison of folate levels in serum, 5MTHF levels in CSF and serum FR autoantibodies among Rett patients from Europe, North America and healthy
controls
Analyte European Rett American Rett European
Controls
American
Controls
Statistical test Significance
(S1) (S2) (S3)
number of patients 33 70 28 1586
age (years) 2 – 19 2.7 – 20.2 1.9 – 19 3 – 19
serum folate
mean 24.36 38.14 24.72 39.38 F-value = 7.62 p = 0.00080
range 8.8 – 62.2 5.4 – 103.1 8.3 – 45 10.2 – 68.6 S1 vs. S2 
S1 vs. S3 
S2 vs. S3 
t-test ( & ) = 3.71
p < 0.01 
NS 
p < 0.01 
p < 0.01
CSF folate
mean 45.53 72.6 82 * 75.7 F-value = 21.879 p < 0.0001
range 12 – 92 27 – 136 44 – 181 40 – 150 S1 vs. S2 
S1 vs. S3 
S2 vs. S3
p < 0.01 
p < 0.01 
NS
number of patients with CFD 14 2 Fisher test ( § )
p = 0.0000
significant
FR antibodies
number 8 unknown 0 Fisher test ( † )
p = 0.011
significant
mean titer 1.25
range 0.29 – 2.04
incidence of FR antibodies for low
vs normal CSF folate
6 / 14 vs 2 / 19 unknown Fisher test
p = 0.037
significant
anticonvulsant drugs in CFD vs
normal CSF folate
7 / 14 vs 8 / 19 Fisher test
p = 0.250
NS
* CSF folate data derived from 99 healthy controls;
S1: Sample representing European Rett patients
S2: Sample representing American Rett patients
S3: Sample representing European healthy controls
§ : Fisher test between European and American Rett patients
† : Fisher test between European Rett patients and healthy controls
& : t-test for comparison between healthy European and American controls 
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lower 5MTHF value in their CSF (analysis of variance F-
value = 21.879 and p < 0.0001; ••Table 2).
In 14 European Rett patients (10 subjects with MECP2 gene
abnormalities and 4 with a normal genotype), the concentration
of 5MTHF in the CSF was below the lower reference limit of
healthy controls ( •• Table 1). However, in 19 patients (11 sub-
jects with an abnormal MECP2 genotype and 8 with a normal
genotype), the 5MTHF concentration in the CSF was within the
normal control range.
Compared to 28 healthy control subjects with no FR autoanti-
bodies, the serum of 8 out of 33 Rett patients from Europe con-
tained blocking FR autoantibodies (a mean of 1.25 pmol FR
blocked / ml of serum; range 0.29 – 2.04; significant Fisher exact
test with probability p = 0.011). The serum of 6 of the 14 patients
with a low folate concentration in the CSF contained autoanti-
bodies against FRs. In contrast, the serum of only 2 of the 19
patients with normal CSF folate levels contained low titers of the
FR autoantibodies (patients 15,26). Comparison of the groups of
Rett patients with low CSF folate and those with normal CSF
folate, showed a significantly higher incidence of FR autoanti-
bodies for the Rett patients with low CSF folate ( •• Table 2; sig-
nificant Fisher exact test p = 0.037). It should be stressed that the
serum of 8 out of 14 Rett patients with low CSF folate, did not
contain FR autoantibodies (patients 7, 11, 13, 18, 19, 22, 24, 32;
•• Table 1). The use of anticonvulsant drugs in 15 of 33 Rett
patients was not found to exert a statistically significant effect
on their folate status ( •• Table 2).
The 8 Rett patients from Northern Europe (patient 1 – 8 from
Germany and Belgium) showed a higher incidence of CSF 5MTHF
deficiency and FR autoantibodies than the 25 Rett patients from
Southern Europe (patients 9 – 33 from Spain and Portugal;
•• Table 3) with a calculated Fisher exact probability at p = 0.005
and p = 0.037 respectively. The serum folate values between
patients from Northern and Southern Europe showed no statis-
tical differences, but comparison of the CSF folate values between
Northern Europe, Southern Europe and healthy controls showed
the lowest CSF folate values for Rett patients from Northern
Europe, followed by moderately lowered CSF folate values for
Rett patients from Southern Europe (analysis of variance F = 20.92
and p < 0.0001; •• Table 3).
The serum folate levels in Rett patients from North-America
(mean value: 38.14 nmol / Liter; range 5.4 – 103.1) were signifi-
cantly higher than the levels in European Rett patients (mean
value: 24.36 nmol / Liter; range 8.8 – 62.2), and healthy European
controls (mean value: 24.72; range 8.3 – 45) using the analysis of
variance for three independent samples (F = 7.62 and
p = 0.000802). Serum folate levels from healthy North-American
girls were also significantly higher than healthy European con-
trols ( •• Table 2).
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Table 3 Comparison of folate levels in serum, 5MTHF levels in CSF and FR autoantibodies between Rett patients from Northern and Southern Europe
Analyte Northern Europe (S1)Southern Europe (S2)Controls (S3) Statistical test Significance
number of patients 8 25 99
serum folate
mean 25.8 23.88 t-test t = 0.33 NS
range 13.2 – 47 8.8 – 62.2
CSF folate
mean 26.8 51.52 82 F-value = 20.92 p < 0.0001
range 12 – 68 33 – 92 44 – 181 S1 vs. S2 p < 0.05
S1 vs. S3 p < 0.01
S2 vs. S3 p < 0.01
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An interesting finding was that among the 12 European Rett
patients with a normal MECP2 genotype, four patients had low
CSF folate levels with FR autoimmunity as contributing factors
in 3 of these 4 patients (patients 1 – 3).
Discussion
&
We have identified autoantibodies against the FRs in 24 % of 33
Rett patients from Europe. This finding suggests a mechanism
for the low CSF concentration of 5MTHF and the accompanying
CFD-like features in these Rett patients. In contrast, a subgroup
of Rett patients with low CSF folate and most Rett patients with
normal CSF folate levels lack these autoantibodies. Furthermore,
two Rett patients with low titers of autoantibodies had normal
CSF folates (patients 15,26). Our study also showed a higher inci-
dence of CFD and FR autoimmunity among the group of Rett
patients residing in North-Western Europe, when compared to
those living in Southern Europe. The lowest CSF folate values
associated with FR autoantibodies were found in the Rett
patients living in Northern Europe.
It is likely that Rett syndrome patients with these autoantibod-
ies in their serum cannot transfer the 5MTHF into the CSF
because the autoantibodies block the binding of folate to the FR
expressed on the choroid plexus and thereby prevent the trans-
fer of folate to the CNS. Our previous study showed that the CSF
of Rett patients with low folate contained a normal concentra-
tion of immunoreactive folate receptor protein that did not bind
radiolabelled folate [1, 2] . These soluble non-functional FR pro-
teins in CSF could represent autoantibody- FR complexes
released into the spinal fluid after cleavage from their GPI-
anchor attachment to the choroid plexus epithelial membranes.
Our observation of circulating FR autoantibodies of the blocking
type in three patients with a Rett phenotype, low CSF folate and
a normal MECP2 genotype may point to a variant of the classical
Rett phenotype that presents as a CFD-like syndrome. However,
the finding of low CSF folate in 1 of the Rett patients with a nor-
mal MECP2 genotype and absence of FR autoimmunity suggests
that other unknown aetiologies can contribute to the low CSF
folate status in the Rett phenotype.
The geographical differences for FR autoimmunity and CFD
has high amino acid sequence homology with the human FR [9]
and may be the source of the antigen. Cross-reactivity of the anti-
bodies generated against the soluble bovine FR with the human
FR antigen may provide a basis of our hypothesis on FR autoim-
munity, which was proposed as a possible mechanism for the
observed FR autoimmunity in children with the infantile-onset
CFD syndrome [5] . The lower incidence of cerebral folate defi-
ciency in the Rett population of North America may be explained
by the folate food fortification and the folate / betaine trial, where
the participants stopped folate at least 30 days or 1 week prior to
lumbar puncture [4] . After folate is incorporated into cells, it
takes more than 90 days before these folate reserves decrease
[10] . Therefore, if folate supplementation is interrupted for less
than 100 days before a lumbar puncture, the results have to be
interpreted with caution. Comparison of the data from America
and Europe has confirmed the significantly higher serum and CSF
folate levels present in the American Rett population. A compari-
son of the incidence of the FR autoantibodies in the two patient
populations from both continents would be an interesting issue
to address in order to explain these conflicting results.
Our finding of low CSF folate in 42 % of Rett patients suggests
that folate transport across the choroid plexus may be blocked.
The presence of serum FR autoantibodies in some of these
patients provides an explanation for their low CSF 5MTHF. How-
ever, in Rett patients where the CSF / plasma folate ratio remains
normal other mechanisms such as an increased folate turnover
due to an increased utilization or catabolism of 5MTHF or other
metabolic abnormalities have to be considered [10] .
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